000117948 001__ 117948
000117948 005__ 20220908120600.0
000117948 0247_ $$2doi$$a10.1016/j.ijcha.2021.100851
000117948 0248_ $$2sideral$$a127043
000117948 037__ $$aART-2021-127043
000117948 041__ $$aeng
000117948 100__ $$aBiccler, J.
000117948 245__ $$aPublic health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK – Results from micro-simulation model
000117948 260__ $$c2021
000117948 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117948 5203_ $$aBackground: Low-dose aspirin therapy reduces the risk of cardiovascular disease and may have a positive effect on the prevention of colorectal cancer. We evaluated the population-level expected effect of regular low-dose aspirin use on cardiovascular disease (CVD), colorectal cancer (CRC), gastrointestinal bleeding, symptomatic peptic ulcers, and intracranial hemorrhage, using a microsimulation study design. Methods: We used individual-level state transition modeling to assess the impact of aspirin in populations aged 50–59 or 60–69 years old indicated for low-dose aspirin usage for primary or secondary CVD prevention. Model parameters were based on data from governmental agencies from the UK or recent publications. Results: In the 50–59 years cohort, a decrease in incidence rates (IRs per 100 000 person years) of non-fatal CVD (-203 and -794) and fatal CVD (-97 and-381) was reported in the primary and secondary CVD prevention setting, respectively. The IR reduction of CRC (-96 and -93) was similar for primary and secondary CVD prevention. The IR increase of non-fatal (116 and 119) and fatal safety events (6 and 6) was similar for primary and secondary CVD prevention. Similar results were obtained for the 60–69 years cohort. Conclusions: The decrease in fatal CVD and CRC events was larger than the increase in fatal safety events and this difference was more pronounced when low-dose aspirin was used for secondary compared to primary CVD prevention. These results provide a comprehensive image of the expected effect of regular low-dose aspirin therapy in a UK population indicated to use aspirin for CVD prevention. © 2021
000117948 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000117948 594__ $$a3.3$$b2021
000117948 592__ $$a0.803$$b2021
000117948 593__ $$aCardiology and Cardiovascular Medicine$$c2021$$dQ2
000117948 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117948 700__ $$aBollaerts, K.
000117948 700__ $$aVora, P.
000117948 700__ $$aSole, E.
000117948 700__ $$aGarcía Rodriguez, L.A.
000117948 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza
000117948 700__ $$aLangley, R.E.
000117948 700__ $$aSoriano Gabarró, M.
000117948 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000117948 773__ $$g36 (2021), 100851 [8 pp]$$tIJC Heart and Vasculature$$x2352-9067
000117948 8564_ $$s317385$$uhttps://zaguan.unizar.es/record/117948/files/texto_completo.pdf$$yVersión publicada
000117948 8564_ $$s2498590$$uhttps://zaguan.unizar.es/record/117948/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117948 909CO $$ooai:zaguan.unizar.es:117948$$particulos$$pdriver
000117948 951__ $$a2022-09-08-11:57:48
000117948 980__ $$aARTICLE